Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
In <i>BRAF</i>-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.
Authors
- C. Vaghi (ORCID: https://orcid.org/0000-0001-5023-3521)
- Iosune Baraibar (ORCID: https://orcid.org/0000-0002-3500-9641)
- R. Dienstmann
- A. García (ORCID: https://orcid.org/0009-0005-5890-6707)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- Élena Elez (ORCID: https://orcid.org/0000-0002-4653-6324)
- Francesc Salvà (ORCID: https://orcid.org/0000-0001-9240-4907)
- Javier Ros (ORCID: https://orcid.org/0000-0002-8137-5415)
- J. Tabernero
- Antonio Alcaraz (ORCID: https://orcid.org/0000-0003-2612-5250)
- Vı́ctor Navarro (ORCID: https://orcid.org/0000-0001-6925-4605)
- M. Gonzalez Rodriguez (ORCID: https://orcid.org/0000-0001-8289-1158)
Institutions
- Vall d'Hebron Hospital Universitari (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100225
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- F. Hoffmann-La Roche
- Les Laboratories Pierre Fabre
- Seagen
- Servier
- Ipsen
- Genentech
- Chugai Pharmaceutical
- Takeda Oncology
- Foundation Medicine
- Medical Research Council
- Daiichi Sankyo Europe